News and Announcements
Meme Capital Management Outperforming the Market
- Published December 07, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Fund is successfully outperforming the market.
- November saw a strong return of +4.39%.
- The strongest performances were by the Property, Information Technology and Energy sectors.
The positive performance of the Fund continued in November with a strong return of +4.39% compared to the broad market’s total return of +1.91%. This most recent result brings the Fund returns since inception to +14.15% per annum, comfortably ahead of the market’s +10.21% and increasing the outperformance since inception in 2013 to +3.94% per annum.
Market returns in November were positive across all sectors apart from Telecommunications, with the strongest performances provided by the Property, Information Technology and Energy sectors. The recent pattern of dominance of the smaller cap stocks continued through November, with the ASX20 returning just 0.97% while the Small Ordinaries (ASX100-ASX300) and Emerging Companies (ASX300+) stocks returned +3.90% and +4.24% respectively. Our active bottom-up investment style guides our portfolio allocations such that they continue to respond to these market performance characteristics as they evolve over time.
About Meme Capital Management Pty Ltd
Meme Capital Management is a West Australian based boutique fund manager specialising in the development of systematic stock market investment strategies to build and protect investor wealth.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
